[Performance evaluation of integrated cytoprotective therapy of different duration in patients with cerebral infarction].

The paper reviews the preliminary results of a multicenter randomized clinical research. The aim of the study was to determine the optimal duration of different types of energy-correction therapy. 99 case report forms of patients with cerebral infarction were reviewed with their prior envelope randomization into three groups. Patients in the first group (experimental group), consisting of 32 patients, as part of combined therapy received ascorbic acid (5% solution twice a day in a recommended dosage of 20 ml/day for 20 days); the second group (37 patients) received 10 ml of cytoflavin intravenously by drop infusion twice a day for 10 days; the third group received cytoflavin for 20 days (from day 1 to day 10 - 20 ml a day, from day 11 to day 20 - 10 ml a day). The average NIH scale score on admission was 14.9 ± 2.6. Prescription of cytoflavin came with average 1.7 - 1.8 time regression (p < 0.05) of the volumes of cerebral ischemia in the of cases of the 10- and 20-day courses of treatment, while there were no significant morphologic changes in the ascorbic acid group. These results correlated with the best dynamics and outcomes of the neurological and performance status of patients receiving cytoflavin. Despite the lack of significant general differences in the clinical and morphological data of the second and third groups, the patients with underlying grave medical condition in the 20-day cytoflavin group (with NIH score of 14-20 points on admission) tended to have improved neurologic status parameters in comparison with the experimental group and the 10-day cytoflavin group. These results attest to the advantages of personalized antioxidant energy-correction therapy.

[Clinical characteristics of hypertensive encephalopathy in the perimenopausal period].

OBJECTIVES: To study correlations between symptoms of hypertensive encephalopathy (HE), structural MRI changes of the brain and affective disorders in the perimenopausal period. MATERIALS AND METHODS: A study included 150 women who have been through natural menopause (group 1) and 100 women in the premenopausal (group 2). Somatic and neurological examination, MRI and psychometric scales for anxiety and depression were used. RESULTS AND CONCLUSIONS: Women with hypertensive encephalopathy in the postmenopausal period had signs of persistent psycho-emotional disorders (higher anxiety, depression of different severity) combined with structural changes in the brain, with their severity increasing with the progression of HE.

[Modern methods of energy homeostasis correction in elderly patients].

In the multicenter randomized clinical-instrumental prospective study 185 patients aged 55-75 years (mean age 68 years) with 94 men and 91 women with cerebral infarction were included. All the patients were hospitalized in the period from 6 to 24 hours from the time of the debut of clinical symptoms, 42,2% of patients scored 14 and above on NIH scale on admission. Patients were randomized into 3 groups: 1st group consisted of 64 patients treated as an antioxidant by 5% solution of ascorbic acid 2 times a day the recommended dose (20 ml/day) for 20 days; 2nd group consisted of 72 patients who received energy monitor Cytoflavin in a daily dose of 20 ml (10.0 ml/drip 2 times a day for 10 days); 3rd group consisted of 49 patients with Cytoflavin therapy extended to 20 days, moreover from 11th to 20th day the dose was 10 ml/day. Cytoflavin treatment was more efficient than ascorbic acid, which can be explained by different pharmacologic mechanisms. Treatment with Cytoflavin for 10 days resulted in a significant decrease of ischemia zone volume by 25% in average, treatment with Cytoflavin for 20 days--by 29%, which manifested in better outcomes in neurologic and functional status. Ascorbic acid demonstrated no effect on morphologic parameters. Patients having at the time of admission 18-20 points according to the NIH and treated with Cytoflavin for 20 days demonstrated significant trend towards improvement of the parameters of the neurological status.

[A comprehensive study of early outcome (at the time of discharge from the hospital) after lumber discectomy for degenerative spine disease]. / Kompleksnoe issledovanie rannikh rezul'tatov (na moment vypiski iz statsionara) posle poiasnichnoi diskéktomii pri degenerativnykh zabolevaniiakh pozvonochnika.

AIM: To find out early outcomes after lumbar discectomy in patients with degenerative spine disease at discharge (10-12 days after surgery) from the hospital. METHODS: The study was performed on 50 patients who have undergone lumbar discectomy for degenerative disc/spine disease in their pre- and post-operative stages of treatment. The study included 50 patients, taking into account both anamnesis and postoperative follow-up data. The outcomes were evaluated using modified Oswestry Disability Index (ODI), Visual Analogue Scale (VAS) and location of pain. RESULTS: The study group consisted of 50 patients who completed the questionnaire in the pre- and post-operative period. The mean age of the patients was 50.0±2.1 years (male-27, female-23). The questionnaire contained questions about severity of pain (VAS), pain tolerance, well-being, walking, standing, sitting and sleeping. The data was compared in the pre- and post-operative stage, differences were evaluated using paired 't' test. There was a significant difference pain severity, walking, standing and sleeping among pre- and post-operative patients. Forty two percent of patients noted significant reduction of pain in the post-operative period. 48% of patients showed normalization of sleep without analgesics and hypnotics. About 72% of patients on the onset of the disease noted pain in both back and leg, and 6% had only low back pain, at the pre-operative stage. 52% of patients had no pain soon after surgery. CONCLUSION: The majority of patients noted an improvement - rapid reduction of pain and restoration of sleep without analgesics and hypnotics in the post-operative period.

[Neurological manifestations of tuberculosis]. / Nevrologicheskie proiavleniia tuberkuleza.

One hundred and forty-four new cases of pulmonary tuberculosis were examined. The examination revealed the following neurological syndromes: vegetovascular dystonia, disseminated cerebral microsymptoms, focal lesion of the brain, sensory polyneuropathy. The presence of positive specific basophilic degranulation reactions and intracutaneous tuberculin test suggests that the body shows allergic reactions in response to Mycobacteria tuberculosis. And since connective tissue that presents in the vessels and tunics in the nervous system is involved into a pathological process in allergy, neurological disorders are always secondary in tuberculosis and due to the primary vascular wall lesion that following the type of secondary allergic vasculitis.